32.41
-0.61(-1.85%)
Currency In USD
| Previous Close | 33.02 |
| Open | 32.78 |
| Day High | 33.67 |
| Day Low | 32.17 |
| 52-Week High | 121.06 |
| 52-Week Low | 27.66 |
| Volume | 1.76M |
| Average Volume | 1.43M |
| Market Cap | 4.21B |
| PE | -7.89 |
| EPS | -4.11 |
| Moving Average 50 Days | 33.24 |
| Moving Average 200 Days | 55.42 |
| Change | -0.61 |
If you invested $1000 in Vaxcyte, Inc. (PCVX) since IPO date, it would be worth $1,239.39 as of September 09, 2025 at a share price of $32.41. Whereas If you bought $1000 worth of Vaxcyte, Inc. (PCVX) shares 3 years ago, it would be worth $1,145.63 as of September 09, 2025 at a share price of $32.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD) Company Intends to Release Topli
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
GlobeNewswire Inc.
Mar 31, 2025 11:00 AM GMT
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunizatio